Toluidine blue O-induced photoinactivation inhibit the biofilm formation of methicillin-resistant Staphylococcus aureus. 2022

Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

BACKGROUND Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to conventional antimicrobial therapies, allowing for high morbidity and mortality. Photodynamic antimicrobial chemotherapy (PACT) is one method that combines visible harmless light with the optimum wavelength with photosensitizers or dyes, producing singlet oxygen (1O2) and reactive oxygen strains (ROS), making permanent damages to the target cells. The purpose of this research is to evaluate the suppression efficacy of toluidine blue O (TBO)-mediated PACT on mature MRSA biofilm in vitro. METHODS In this study, the 48 h mature biofilm of the multidrug-resistant Staphylococcus aureus strain MRSA252 was used. The photodynamic therapy (PDT) group was treated with different concentrations of TBO (0.5, 0.75, 1.0 or 1.25 µM) and different doses of red light (635 ± 5 nm wavelength; 30 or 50 J/cm2). The biofilms viability after PDT were evaluated by crystal violet (CV) staining assay and {2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetra-zolium hydroxide} (XTT) assay; meanwhile, the morphological changes were detected by confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM), separately. Moreover, the biofilms virulence was evaluated by red blood cell (RBC) hemolysis assay and staphylococcal virulence factor enterotoxins A (SEA) detected by enzyme linked immunosorbent assay (ELISA). After PDT, the biofilm was re-cultured for extra 48 h. Its formation viability and virulence were detected again. All data were analyzed by ANOVAs followed by the Games Howell post hoc test (α = 0.05). RESULTS The biofilm was inactivated about 2.3 log10 at 1.25 µM with 30 J/cm2 illumination, and 3.5 log10 with 50 J/cm2 after PDT (P<0.05). XTT assays demonstrated the viability of mature MRSA biofilms was reduced after PACT. PDT group shows a distinct reduction in RBC hemolysis rate and the concentration of SEA compared to the control groups. The morphological features of the biofilms showed great changes, such as shrinkage, fissure, fragmentation, and rarefaction after being treated by TBO-PDT and observed by SEM. The recovery of the structure and virulence of biofilm were suppressed after PDT. CONCLUSIONS TBO-mediated PDT could destroy the biofilm structure, reduce its virulence and depress its self-recovery.

UI MeSH Term Description Entries
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014048 Tolonium Chloride A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery. Toluidine Blue O,CI-52040,Toluidine Blue,Blue O, Toluidine,Blue, Toluidine,CI 52040,CI52040,Chloride, Tolonium
D017319 Photosensitizing Agents Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. Photosensitizer,Photosensitizers,Photosensitizing Agent,Photosensitizing Effect,Photosensitizing Effects,Agent, Photosensitizing,Agents, Photosensitizing,Effect, Photosensitizing,Effects, Photosensitizing
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D018441 Biofilms Encrustations formed from microbes (bacteria, algae, fungi, plankton, or protozoa) embedded in an EXTRACELLULAR POLYMERIC SUBSTANCE MATRIX that is secreted by the microbes. They occur on body surfaces such as teeth (DENTAL DEPOSITS); inanimate objects, and bodies of water. Biofilms are prevented from forming by treating surfaces with DENTIFRICES; DISINFECTANTS; ANTI-INFECTIVE AGENTS; and anti-fouling agents. Biofilm

Related Publications

Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
February 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
October 2020, Journal of ethnopharmacology,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
June 2017, Chemical communications (Cambridge, England),
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
November 2022, Communications biology,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
January 2023, International journal of molecular sciences,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
November 2023, Diseases (Basel, Switzerland),
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
January 2011, PloS one,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
July 2016, Iranian biomedical journal,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
January 2024, Microbiology spectrum,
Yaxiong He, and Jiaying Pang, and Zengjun Yang, and Mengxue Zheng, and Yanlan Yu, and Zhiyong Liu, and Baohua Zhao, and Guangyun Hu, and Rui Yin
January 2021, Biochemical and biophysical research communications,
Copied contents to your clipboard!